Our top pick for
R1 RCM Inc is a health information services business based in the US. R1 RCM shares (RCM) are listed on the NASDAQ and all prices are listed in US Dollars. R1 RCM employs 19,000 staff and has a trailing 12-month revenue of around 0.00.
|Latest market close||$22.76|
|52-week range||$16.62 - $31.28|
|50-day moving average||$21.31|
|200-day moving average||$22.46|
|Wall St. target price||$31.16|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-2.76|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-10-15)||1.11%|
|1 month (2021-09-22)||5.37%|
|3 months (2021-07-22)||10.38%|
|6 months (2021-04-22)||-12.90%|
|1 year (2020-10-22)||30.88%|
|2 years (2019-10-22)||122.27%|
|3 years (2018-10-22)||161.61%|
|5 years (2016-10-21)||860.34%|
Valuing R1 RCM stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of R1 RCM's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
R1 RCM's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 1.403. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into R1 RCM's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
R1 RCM's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $214 million.
The EBITDA is a measure of a R1 RCM's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||$1.3 billion|
|Operating margin TTM||10.77%|
|Gross profit TTM||$249.7 million|
|Return on assets TTM||7.73%|
|Return on equity TTM||42.08%|
|Market capitalisation||$6.3 billion|
TTM: trailing 12 months
There are currently 4.9 million R1 RCM shares held short by investors – that's known as R1 RCM's "short interest". This figure is 0.3% down from 4.9 million last month.
There are a few different ways that this level of interest in shorting R1 RCM shares can be evaluated.
R1 RCM's "short interest ratio" (SIR) is the quantity of R1 RCM shares currently shorted divided by the average quantity of R1 RCM shares traded daily (recently around 1.1 million). R1 RCM's SIR currently stands at 4.39. In other words for every 100,000 R1 RCM shares traded daily on the market, roughly 4390 shares are currently held short.
However R1 RCM's short interest can also be evaluated against the total number of R1 RCM shares, or, against the total number of tradable R1 RCM shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case R1 RCM's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 R1 RCM shares in existence, roughly 20 shares are currently held short) or 0.0358% of the tradable shares (for every 100,000 tradable R1 RCM shares, roughly 36 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against R1 RCM.
Find out more about how you can short R1 RCM stock.
We're not expecting R1 RCM to pay a dividend over the next 12 months.
Over the last 12 months, R1 RCM's shares have ranged in value from as little as $16.62 up to $31.28. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while R1 RCM's is 0.7619. This would suggest that R1 RCM's shares are less volatile than average (for this exchange).
R1 RCM Inc. provides revenue cycle management (RCM) for healthcare providers in the United States. The company offers end-to-end RCM services to manage their revenue cycle operations that encompass patient registration, insurance and benefit verification, medical treatment documentation and coding, bill preparation, and collections from patients and payers. It also provides modular services comprising physician advisory services, which assists healthcare organizations in complying with payer requirements regarding whether to classify a hospital visit as an in-patient or an out-patient observation case for billing purposes; practice management services that offers administrative and operational support for patient care and outsource non-core functions; revenue integrity solutions, including charge capture, charge description master maintenance, and pricing services; coding management services, such as business intelligence and analysis, human capital management, accountability framework, and quality management programs; patient experience; and business office services. In addition, the company offers software-as-a-service based scheduling and patient access solutions. It serves healthcare providers, including health systems, hospitals, and physician groups. The company was formerly known as Accretive Health, Inc.
Steps to owning and managing ProShares Bitcoin Strategy ETF units.
Everything we know about the The Real Good Food Company IPO, plus information on how to buy in.
Everything we know about the Lulu’s Fashion Lounge Holdings IPO, plus information on how to buy in.
Everything we know about the Allarity Therapeutics IPO, plus information on how to buy in.
Everything we know about the Jupiter Neurosciences IPO, plus information on how to buy in.
Everything we know about the Mainz Biomed IPO, plus information on how to buy in.
Everything we know about the Progressive Care IPO, plus information on how to buy in.
Everything we know about the Desert Peak Minerals IPO, plus information on how to buy in.
Everything we know about the Vaxxinity IPO, plus information on how to buy in.
Everything we know about the Entrada Therapeutics IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.